Comparative Pharmacology
Head-to-head clinical analysis: ALOMIDE versus CROLOM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOMIDE versus CROLOM.
ALOMIDE vs CROLOM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lodoxamide stabilizes mast cells by preventing antigen-induced release of histamine and other inflammatory mediators (e.g., SRS-A) from the mast cell, possibly by inhibiting calcium influx.
CROLOM is a selective estrogen receptor modulator (SERM) that binds to estrogen receptors, blocking estrogen-mediated signaling in target tissues, thereby inhibiting growth of hormone-sensitive breast cancer cells.
1 to 2 drops in each affected eye four times daily (every 6 hours).
2 capsules (each containing 40 mg cromolyn sodium) orally 4 times daily, 30 minutes before meals and at bedtime.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours. Clinically, this short half-life supports frequent dosing for sustained ocular effects.
Terminal half-life 8-12 hours in normal renal function; extended to 20-30 hours in severe impairment
Primarily renal excretion; approximately 50-60% of the dose is excreted unchanged in urine within 24 hours. Fecal elimination accounts for less than 10%. Minor biliary excretion.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer